Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

C
2001
Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Therapy of CLL

Favorite
2014
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Therapy of CLL

Favorite
1216
Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Pathogenesis of CLL

Favorite
1019
Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Pathogenesis of CLL

Favorite
1036
Chronic lymphocytic leukemia extracellular vesicles induce the differentiation of monocytes into nurse-like cells
Pathogenesis of CLL

Favorite
4001
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Pathogenesis of CLL

Favorite
1203
Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Past, Present, and Future in CLL

Favorite
1160
Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Clinical Challenges in CLL

Favorite
1106
Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Therapy of CLL

Favorite
1014
Clonal architecture and single-cell transcriptome landscape in Richter’s syndrome
Clinical Challenges in CLL

Favorite
1032
Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Clinical Challenges in CLL

Favorite
1057
Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Pathogenesis of CLL

Favorite
1227
Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil
Therapy of CLL

Favorite
1015
Coupled effect of a miR-155 deficiency and hypoxia conditions leads to the upregulation of SLC2A1 (GLUT1), SLC2A3 (GLUT3) and EGLN1 genes in the leukemic B-cells
Pathogenesis of CLL

Favorite
2019
Covalent menin inhibitor, BMF-219, impacts key gene signatures and molecular pathways in Chronic Lymphocytic Leukemia patient-derived models
Therapy of CLL

Favorite
3003
COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Therapy of CLL

Favorite
1133
COVID-19 infection in chronic lymphocytic leukemia (CLL) patients treated with venetoclax: a Danish single-center experience
Clinical Challenges in CLL

Favorite
1025
Curcumin enhances ibrutinib induced killing effect against TP53-mutated Chronic Lymphocytic Leukemia cells in vitro
Clinical Challenges in CLL

Favorite